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Summary
Background Survival from colorectal cancer has been shown to be lower in Denmark and England than in comparable 
high-income countries. We used data from national colorectal cancer registries to assess whether differences in the 
proportion of patients receiving resectional surgery could contribute to international differences in colorectal cancer 
survival.
Methods In this population-based study, we collected data from all patients aged 18–99 years diagnosed with primary, 
invasive, colorectal adenocarcinoma from Jan 1, 2010, to Dec 31, 2012, in Denmark, England, Norway, and Sweden, 
from national colo rectal cancer registries. We estimated age-standardised net survival using multivariable modelling, 
and we compared the proportion of patients receiving resectional surgery by stage and age. We used logistic regression 
to predict the resectional surgery status patients would have had if they had been treated as in the best performing 
country, given their individual characteristics.
Findings We extracted registry data for 139 457 adult patients with invasive colorectal adenocarcinoma: 12 958 patients in 
Denmark, 97 466 in England, 11 450 in Norway, and 17 583 in Sweden. 3-year colon cancer survival was lower in England 
(63·9%, 95% CI 63·5–64·3) and Denmark (65·7%, 64·7–66·8) than in Norway (69·5%, 68·4–70·5) and Sweden (72·1%, 
71·2–73·0). Rectal cancer survival was lower in England (69·7%, 69·1–70·3) than in the other three countries (Denmark 
72·5%, 71·1–74·0; Sweden 74·1%, 72·7–75·4; and Norway 75·0%, 73·1–76·8). We found no significant differences in 
survival for patients with stage I disease in any of the four countries. 3-year survival after stage II or III rectal cancer and 
stage IV colon cancer was consistently lower in England (stage II rectal cancer 86·4%, 95% CI 85·0–87·6; stage III rectal 
cancer 75·5%, 74·2–76·7; and stage IV colon cancer 20·5%, 19·9–21·1) than in Norway (94·1%, 91·5–96·0; 83·4%, 
80·1–86·1; and 33·0%, 31·0–35·1) and Sweden (92·9%, 90·8–94·6; 80·6%, 78·2–82·7; and 23·7%, 22·0–25·3). 3-year 
survival after stage II rectal cancer and stage IV colon cancer was also lower in England than in Denmark (stage II rectal 
cancer 91·2%, 88·8–93·1; and stage IV colon cancer 23·5%, 21·9–25·1). The total proportion of patients treated with 
resectional surgery ranged from 47 803 (68·4%) of 69 867 patients in England to 9582 (81·3%) of 11 786 in Sweden for 
colon cancer, and from 16 544 (59·9%) of 27 599 in England to 4106 (70·8%) of 5797 in Sweden for rectal cancer. This 
range was widest for patients older than 75 years (colon cancer 19 078 [59·7%] of 31 946 patients in England to 
4429 [80·9%] of 5474 in Sweden; rectal cancer 4663 [45·7%] of 10 195 in England to 1342 [61·9%] of 2169 in Sweden), 
and the proportion of patients treated with resectional surgery was consistently lowest in England. The age gradient of 
the decline in the proportion of patients treated with resectional surgery was steeper in England than in the other 
three countries in all stage categories. In the hypothetical scenario where all patients were treated as in Sweden, given 
their age, sex, and disease stage, the largest increase in resectional surgery would be for patients with stage III rectal 
cancer in England (increasing from 70·3% to 88·2%).
Interpretation Survival from colon cancer and rectal cancer in England and colon cancer in Denmark was lower than 
in Norway and Sweden. Survival paralleled the relative provision of resectional surgery in these countries. Differences 
in patient selection for surgery, especially in patients older than 75 years or individuals with advanced disease, might 
partly explain these differences in international colorectal cancer survival.
Funding Early Diagnosis Policy Research Grant from Cancer Research UK (C7923/A18348).
Copyright 2018 © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Colorectal cancer is among the three most common 
cancer diagnoses and causes of cancer death in women 
and men in Denmark, Norway, Sweden, and the UK.1 
The deficit in survival from colorectal cancer seen in 
Denmark and England compared with that of Norway and 
Sweden2–4 might be explained partly by differences in 
disease stage distribution, arising from delays in 
diagnosis.5 The variations in stage-specific survival also 
suggest differences in treatment.5
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The primary treatment for colorectal cancer is surgical 
removal of the main tumour or tumours and affected 
tissues. Total mesorectal excision became the standard 
surgery for rectal cancer in Denmark, Norway, and 
Sweden in the mid-1990s6–8 and some years later in 
England.9 This technique entails the removal of the rec-
tum and surrounding tissues, including lymph nodes and 
fascia,10 and requires particular surgical training and skills 
to secure good results. The surgical principle of resection 
in the embryological plane, which is used in mesorectal 
excision, was later applied to colon cancer surgery, with 
favourable results in terms of recurrences and survival.11,12
Preoperative (neo-adjuvant) or postoperative (adjuvant) 
radiotherapy or chemotherapy can be used to reduce the 
risk of recurrence and treat micrometastases.13,14 The 
decision to treat patients with colorectal cancer with 
neo-adjuvant or adjuvant therapy depends on the extent 
of disease and risk of recurrence. In general, clinical 
guide lines do not recommend additional therapy for 
early-stage colon tumours or rectal tumours treated with 
surgery with adequate resection margins.13–15 The use of 
neo-adjuvant or adjuvant therapy for stage II or III 
tumours is variable between—and within16—countries, 
particularly for rectal tumours.17
We used population-based data from national color-
ectal cancer registries to estimate stage-specific and 
age-standardised net survival at 3 years of patients 
diagnosed with colorectal cancer in Denmark, England, 
Norway, and Sweden, and to compare the proportions of 
patients receiving resectional surgery in those countries 
by patient and tumour characteristics.
Methods
Study design and data sources
In this population-based study, we included all patients 
aged 18–99 years diagnosed with primary, invasive 
colorectal adenocarcinomas from Jan 1, 2010, to 
Dec 31, 2012. Patients diagnosed by their death 
certification alone and patients with records with invalid 
date sequences were excluded.18 In Denmark, England, 
and Norway, we extracted data from population-based 
national cancer registries. By linking individual patient 
records in Denmark to the Danish Colorectal Cancer 
Group database,19 additional clinical information was 
available for 11 746 (90·7%) patients registered with 
colorectal adenocarcino mas in the Danish National 
Cancer Registry. Similarly, 97 185 (99·7%) English 
national cancer registry records for patients with 
colorectal cancer were linked to at least one of the 
National Bowel Cancer Audit data, Hospital Episode 
Statistics inpatient and outpatient records, and the 
Cancer Waiting Times Monitoring Data Set. Norwegian 
national cancer registry data are routinely linked to 
the Norwegian Colorectal Cancer Registry, a specialised 
registry that contains detailed clinical infor mation on all 
patients with colorectal cancer nationwide.8 The Swedish 
Research in context
Evidence before this study
To identify previous population-based international 
comparisons of colorectal cancer survival and treatment, 
we searched PubMed for articles published between 
Jan 1, 1980, and Jan 31, 2018, using the terms 
“population-based”, “cancer”, “survival”, “treatment”, 
“international”, “colorectal OR colon OR rectum”, without 
language restrictions. We manually searched the 95 references 
retrieved. In total, 22 articles assessed colorectal cancer 
outcomes in at least one of the countries included in our study. 
Additionally, we examined secondary references, national and 
international clinical guidelines, and other national reports for 
information on colorectal cancer management. Previous 
research showed that colorectal cancer survival was lower in 
England and Denmark than in other high-income countries 
with similar health-care coverage. The deficit in survival was 
partly explained by a more advanced stage distribution in 
Denmark and, potentially, by suboptimal care in England. 
Analysts who did this research pointed to the need for research 
into differences in stage-specific treatment between these 
countries.
Added value of this study
We used national population-based clinical data to compare 
stage-specific survival of patients diagnosed with primary 
colorectal adenocarcinoma in Denmark, England, Norway, 
and Sweden between 2010 and 2012, and to assess whether 
the international survival differences could be explained by 
differences in patient care. We considered stage-specific survival 
differences in relation to the proportion of patients who 
received resectional surgery. We showed that net survival up to 
3 years after colon cancer was substantially lower in England 
and Denmark than in Norway and Sweden, and survival from 
rectal cancer was lower in England than in the other three 
countries. International differences were wider for patients with 
more advanced disease stage. The probability of receiving 
resectional surgery paralleled the survival outcomes, with 
patients in England substantially less likely to receive 
resectional surgery than in the other three countries. We also 
found a steep declining age gradient in the probability of 
receiving resectional surgery in England, which was less 
noticeable or not evident in the other countries.
Implications of all the available evidence
These findings have important policy implications, showing 
that the colorectal cancer survival deficit in England can be 
attributed partly to shortfalls in treatment. Patients older than 
75 years, in particular, are less likely to receive surgery than 
patients with the same characteristics in Denmark, Norway, and 
Sweden. We highlight the need for more patient data on 
comorbidities, frailty, and additional therapies to understand 
these differences better.
For more on the Danish 
Colorectal Cancer Group see 
http://www.DCCG.dk 
For the National Bowel Cancer 
Audit see https://www.nboca.
org.uk/
For the Hospital Episode 
Statistics see https://www.
digital.nhs.uk/data-and-
information/data-tools-and-
services/data-services/
hospital-episode-statistics 
For the Cancer Waiting Times 
Monitoring Data Set see 
https://digital.nhs.uk/data-and-
information/data-collections-
and-data-sets/data-collections/
cancerwaitingtimescwt
For the Norwegian Colorectal 
Cancer Registry see https://
www.kreftregisteret.no/en/The-
Registries/Clinical-Registries/
Colorectal-Cancer-Registry/
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For more on the Swedish 
Colorectal Cancer Registry see 
https://www.cancercentrum.se/
samverkan/cancerdiagnoser/
tjocktarm-andtarm-och-anal/
tjock--och-andtarm/
kvalitetsregister/
Colorectal Cancer Registry provided clinical data on 
patients with colorectal cancer in Sweden;7 its coverage 
for the study period was near complete.20 Definitions of 
clinical variables (site, stage, or treatment) were agreed 
with in-country clinicians and specialised cancer registry 
staff to reconcile differences in coding between the 
various data sources. The data specifications were agreed 
in advance with other countries through a prespecified 
data protocol. Some further discussions with clinicians 
and registry staff were held to understand and reconcile 
differences in coding and clinical practices in those 
countries.
 All patients included in this study were followed up 
from time of diagnosis until death or until Dec 31, 2014, 
whichever occurred first. Last vital status was assessed by 
linking data to national death registry records. 
Procedures
Colon cancer was defined by topographical codes C18.0–
C19.9 and rectal cancer by codes C20.0–C20.9 of the 
International Classification of Diseases for Oncology, 
3rd edition.21 Tumours located 15 cm or less from the 
anal verge were considered rectal cancers. Tumours with 
morphological codes for non-adenocarcinoma were 
excluded from analyses.
We applied consistent quality control measures to all 
records (appendix pp 1–2).18 In cases of multiple tumours 
diagnosed at the same site within 6 months of each other, 
we retained the date of diagnosis of the first tumour; 
where stage and type of surgery were inconsistent 
between records (n=327, 0·23%), we selected the most 
advanced stage and most extensive surgery. For all 
patients with record of more than one surgery, we 
selected the most extensive surgery.
Disease extent (stage), as defined by the Union for 
International Cancer Control TNM classification of 
malignant tumours, was characterised by applying a 
hierarchical algorithm previously described.22 Priority 
was given to pathological confirmation of tumour, lymph 
node extension, and distant metastases (if positive), over 
clinical TNM components. During 2010–12, Denmark 
and England used the 5th edition of TNM in their 
colorectal cancer registries, whereas the 7th edition was 
used in Norway and Sweden. There is broad comparability 
between the main stage categories among these TNM 
editions.22
We defined resectional surgery as the surgical removal of 
the primary tumour, irrespective of the intent and outcome 
of surgery, done within 9 months of diagnosis. Information 
regarding surgery for each patient was extracted from the 
specialised registry data for Denmark, Norway, and 
Sweden. For England, we derived this information from 
Hospital Episode Statistics and National Bowel Cancer 
Audit records, by identifying relevant codes from the 
Classification of Intervention and Procedures of the Office 
of Population Censuses and Surveys (OPCS), version 4.7 
(OPCS 4.7),23 a standard classification of procedures done 
in National Health Service (NHS) hospitals in England. 
Local excisions were considered radical for stage I tumours 
alone. Non-resectional procedures that were purely 
diagnostic or symptom-alleviating (eg, stoma) were not 
considered as resectional surgery. In Denmark and 
England, surgical status was categorised as missing when 
patients were registered in the national cancer registry but 
were not recorded in the specialised colorectal cancer 
registry (or in Hospital Episode Statistics for England). We 
calculated the potential range of the proportion of patients 
that might have had resectional surgery in Denmark and 
England, first assuming that all patients with missing data 
were treated and then assuming that they were all 
untreated. We then estimated upper and lower limits of 
the probable distribution of resectional surgery in each of 
these countries. 
Information regarding radiotherapy and planned 
chemo therapy within 6 months of diagnosis was extracted 
from colorectal cancer registry data in Denmark, Norway, 
and Sweden, and from National Bowel Cancer Audit and 
Cancer Waiting Times records in England.
We hold approvals from the UK Health Research 
Authority (reference ECC 3–04(i)/2011), the National 
Health Service Research Ethics Service (11/LO/0331), and 
the London School of Hygiene & Tropical Medicine 
(LSHTM, 12171). We have a data proces sing agreement 
with the Danish Cancer Society and approval from the 
Danish Data Protection Agency to use data from the 
Danish Colorectal Cancer Group; a data disclosure 
agreement with the Cancer Registry of Norway to use the 
Norwegian data; and ethical approval from the Regional 
Ethical Committee in Uppsala to use the Swedish data. 
Data preparation and analyses were done at the London 
School of Hygiene & Tropical Medicine. Data were 
extracted and transferred with a standard data structure 
protocol and file transmission procedure, in line with the 
CONCORD programme for the global surveillance of 
cancer survival.24
Outcomes
Our primary aim was to assess the estimated age-
standardised net survival up to 3 years after diagnosis by 
country and disease stage and the estimated probability of 
patients receiving resectional surgery by stage and age in 
each country. We also estimated the hypothetical change in 
the probability of receiving resectional surgery that patients 
would have had if they had been treated as in the best 
performing country, given their individual characteristics.
Statistical analysis
We compared the demographic and clinical character-
istics of patients with colorectal cancer diagnosed in 
Denmark, England, Norway, and Sweden, including 
patients’ age, sex, and disease stage. We estimated net 
survival up to 3 years after diagnosis by country and 
disease stage, using the complete approach.25 Net survival 
controls for the hazard of death from other causes 
See Online for appendix
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(background mortality) and is suitable for use in inter-
national comparisons of survival because background 
mortality differs between countries. In the absence of 
reliable information on the cause of death, the 
background mortality hazard was provided by life tables 
for the general population defined by country, sex, single 
year of age, and year.26 We used a multivariable modelling 
approach to estimate the excess mortality hazard (ie, due 
to colorectal cancer) and predict net survival. Survival 
models were stratified by country and disease stage. We 
used a model selection strategy to test for non-linearity 
and time dependence of the effects of sex and age on the 
excess mortality hazard and their interactions.27 Survival 
was predicted by age group, defined by the International 
Cancer Survival Standard. We used International Cancer 
Survival Standard weights to produce a weighted average 
of the survival estimates (age-standardisation), to allow 
for differences between countries in the age distribution 
of the population of patients with cancer.28 We used the 
Stata command strcs to fit flexible parametric survival 
models on the log-hazard scale.29
We used multivariate logistic regression models to 
compare the probability of receiving resectional surgery 
between countries. Models were developed for each 
disease stage and initially included country, age, and sex. 
We started with a full, saturated model that included 
main effects and all potential interactions. The main 
effects and important interactions between country and 
age were kept a priori, and we considered other inter-
actions on the basis of the likelihood ratio test. Non-
linearity was assessed by comparing the model with age 
as a categorical variable against a model with age as a 
continuous variable. If categorical age was chosen, the 
non-linear effect of age was modelled by use of a 
restricted cubic spline variable. Subsequently, we applied 
the model coefficients of the best performing country to 
individuals from the other countries, to assess the 
hypothetical change in the probability of receiving 
resectional surgery if patients had been treated as in the 
best performing country, given their observed character-
istics. We used Stata 15 software for all statistical 
analyses.30
Colon tumours Rectal tumours
Denmark England Norway Sweden Denmark England Norway Sweden
Mean age, years (SD) 71·9 (11·3) 72·4 (12·0) 72·6 (11·9) 72·7 (11·5) 69·5 (11·5) 70·0 (12·2) 69·9 (12·2) 70·3 (11·9)
Age group, years
18–54 660 (7·7%) 5700 (8·2%) 656 (7·9%) 863 (7·3%) 481 (11·0%) 3109 (11·3%) 346 (11·1%) 626 (10·8%)
55–64 1480 (17·3%) 11 818 (16·9%) 1345 (16·1%) 1796 (15·2%) 935 (21·3%) 5936 (21·5%) 679 (21·8%) 1102 (19·0%)
65–74 2841 (33·2%) 20 403 (29·2%) 2441 (29·3%) 3653 (31·0%) 1502 (34·2%) 8359 (30·3%) 946 (30·4%) 1900 (32·8%)
75–84 2567 (30·0%) 21 942 (31·4%) 2670 (32·0%) 3907 (33·1%) 1107 (25·2%) 7289 (26·4%) 809 (26·0%) 1580 (27·3%)
85–99 1019 (11·9%) 10 004 (14·3%) 1227 (14·7%) 1567 (13·3%) 366 (8·3%) 2906 (10·5%) 331 (10·6%) 589 (10·2%)
Sex
Men 4160 (48·6%) 37 279 (53·4%) 4087 (49·0%) 5875 (49·8%) 2670 (60·8%) 17 700 (64·1%) 1836 (59·0%) 3421 (59·0%)
Women 4407 (51·4%) 32 588 (46·6%) 4252 (51·0%) 5911 (50·2%) 1721 (39·2%) 9899 (35·9%) 1275 (41·0%) 2376 (41·0%)
Disease stage at diagnosis*
Stage I 839 (10·7%) 7413 (12·8%) 972 (13·0%) 1462 (13·0%) 793 (20·7%) 5674 (24·4%) 705 (26·0%) 1247 (23·3%)
Stage II 2723 (34·7%) 17 524 (30·3%) 2482 (33·2%) 3648 (32·5%) 1032 (27·0%) 5014 (21·6%) 659 (24·3%) 1264 (23·6%)
Stage III 2036 (25·9%) 17 258 (29·8%) 1931 (25·9%) 3436 (30·6%) 1062 (27·8%) 7520 (32·4%) 645 (23·8%) 1551 (29·0%)
Stage IV 2256 (28·7%) 15 679 (27·1%) 2081 (27·9%) 2670 (23·8%) 935 (24·5%) 5026 (21·6%) 699 (25·8%) 1294 (24·2%)
Unknown stage 713 (8·3%) 11 993 (17·2%) 873 (10·5%) 570 (4·8%) 569 (13·0%) 4365 (15·8%) 403 (13·0%) 441 (7·6%)
Received resectional 
surgery†
6040 (70·5%) 47 803 (68·4%) 6023 (72·2%) 9582 (81·3%) 2982 (67·9%) 16 544 (59·9%) 2064 (66·3%) 4106 (70·8%)
Received radiotherapy‡ 134 (1·6%) 2097 (3·0%) 109 (1·3%) 54 (0·5%) 1182 (26·9%) 11 299 (40·9%) 1321 (42·5%) 2935 (50·6%)
Received 
chemotherapy‡§
3272 (38·2%) 18 640 (26·7%) 1654 (19·8%) 2525 (21·4%) 2060 (46·9%) 8484 (30·7%) 931 (29·9%) 1404 (24·2%)
Unknown treatment 
status¶
949 (11·1%) 214 (0·3%) 0 (0·0%) 0 (0·0%) 263 (6·0%) 67 (0·2%) 0 (0·0%) 0 (0·0%)
Total 8567 (100%) 69 867 (100%) 8339 (100%) 11 786 (100%) 4391 (100%) 27 599 (100%) 3111 (100%) 5797 (100%)
Data are n (%), unless otherwise specified. *Proportions of total number of patients with known stage. †Defined as surgery to remove the primary tumour within 9 months of diagnosis, excluding diagnostic and 
palliative procedures. ‡Received within 6 months of diagnosis; sources and completeness of information on chemotherapy or radiotherapy varied greatly between countries, with a high proportion of missing 
information in England. §Planned chemotherapy in Norway and Sweden. ¶Proportion of patients not registered in specialised colorectal cancer registries (or Hospital Episode Statistics, Cancer Waiting Times 
Monitoring Data Set for England). 
Table 1: Characteristics of patients diagnosed with colorectal adenocarcinoma, 2010–12
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Role of the funding source
The funders of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the manuscript. The corresponding author had full access 
to all the data in the study, and the final responsibility for 
the decision to submit for publication.
Results
We included information from 139 457 patients diagnosed 
with colorectal adenocarcinoma in England, Denmark, 
Norway, and Sweden in our analyses. The distribution by 
topographical site varied slightly between countries. 
The age distri bution of patients was similar between 
countries, with patients with rectal cancer being younger 
than patients with colon cancer overall (table 1). Median 
follow-up was similar between countries (table 2). 
Disease stage was known for 11 676 (90·1%) of 
12 958 patients in Denmark, 81 108 (83·2%) of 97 466 in 
England, 10 174 (88·9%) of 11 450 in Norway, and 16 572 
(94·3%) of 17 583 in Sweden. In patients with known 
disease stage, the proportion diagnosed with stage I–III 
colon cancer was higher in Sweden than in England, 
Colon tumours Rectal tumours
Denmark England Norway Sweden Denmark England Norway Sweden
Median follow-up time, years (IQR) 2·5 
(0·9–3·5)
2·4 
(0·7–3·5)
2·5 
(1·1–3·7)
2·7 
(1·4–3·7)
2·7 
(1·5–3·7)
2·6 
(1·4–3·6)
2·8 
(1·9–3·8)
2·8 
(1·8–3·8)
1-year net survival (95% CI)
All stages 80·3 
(79·5–81·0)
78·2 
(77·9–78·5)
80·9 
(80·1–81·6)
83·9 
(83·3–84·5)
85·5 
(84·5–86·5)
84·6 
(84·2–85·0)
87·4 
(86·0–88·6)
87·6 
(86·7–88·5)
Stage I 97·1 
(95·6–98·1)
98·7 
(97·8–99·2)
98·2 
(96·4–99·1)
100 
(100·0–100·0)
98·0 
(95·8–99·1)
98·8 
(98·2–99·1)
98·4 
(95·9–99·4)
99·8 
(99·6–99·9)
Stage II 94·5 
(93·4–95·4)
94·9 
(94·6–95·3)
95·5 
(94·4–96·3)
96·8 
(96·1–97·4)
95·3 
(93·9–96·3)
94·6 
(93·8–95·3)
99·8 
(99·8–99·8)
97·5 
(96·1–98·4)
Stage III 87·8 
(86·4–89·2)
87·5 
(87·1–88·0)
89·3 
(87·8–90·6)
90·7 
(89·7–91·6)
90·0 
(87·9–91·7)
91·1 
(90·4–91·8)
93·9 
(92·3–95·2)
93·6 
(92·1–94·8)
Stage IV 52·9 
(51·3–54·5)
48·4 
(47·8–49·1)
57·3 
(55·4–59·1)
51·9 
(50·2–53·6)
61·6 
(59·3–63·9)
60·0 
(58·9–61·0)
66·6 
(63·8–69·2)
61·5 
(59·4–63·6)
Unknown stage 62·8 
(60·2–65·4)
62·2 
(61·3–63·0)
58·0 
(55·0–60·8)
78·9 
(76·1–81·4)
78·9 
(75·9–81·6)
72·7 
(71·6–73·8)
75·2 
(71·8–78·2)
83·1 
(80·4–85·5)
2-year net survival (95% CI)
All stages 71·9 
(71·0–72·8)
69·9 
(69·5–70·2)
73·9 
(73·0–74·8)
76·7 
(75·9–77·5)
78·2 
(76·9–79·4)
76·2 
(75·7–76·8)
80·3 
(78·6–81·8)
79·8 
(78·6–81·0)
Stage I 96·2 
(94·3–97·5)
98·2 
(97·1–98·9)
98·2 
(96·4–99·1)
99·5 
(97·2–100·0)
97·0 
(93·9–98·6)
97·8 
(96·9–98·4)
98·4 
(95·9–99·4)
99·8 
(97·5–100·0)
Stage II 92·3 
(90·9–93·5)
92·7 
(92·2–93·2)
94·7 
(93·4–95·7)
95·3 
(94·3–96·2)
93·0 
(91·1–94·5)
90·3 
(89·2–91·3)
98·9 
(98·0–99·4)
95·1 
(93·2–96·4)
Stage III 81·4 
(79·6–83·1)
80·1 
(79·5–80·7)
82·1 
(80·2–83·8)
84·0 
(82·7–85·3)
83·0 
(80·2–85·4)
82·9 
(81·9–83·9)
88·2 
(85·7–90·3)
86·8 
(84·9–88·6)
Stage IV 34·4 
(32·8–36·1)
30·5 
(29·9–31·1)
41·9 
(39·9–44·0)
33·6 
(31·8–35·3)
42·4 
(39·9–44·9)
39·7 
(38·6–40·8)
49·6 
(46·6–52·4)
39·8 
(37·7–42·0)
Unknown stage 53·2 
(50·4–56·0)
52·8 
(51·9–53·8)
49·8 
(46·6–52·8)
73·0 
(69·8–75·9)
72·0 
(68·4–75·2)
63·5 
(62·1–64·7)
64·2 
(60·3–67·9)
77·1 
(73·9–79·9)
3-year net survival (95% CI)
All stages 65·7 
(64·7–66·8)
63·9 
(63·5–64·3)
69·5 
(68·4–70·5)
72·1 
(71·2–73·0)
72·5 
(71·1–74·0)
69·7 
(69·1–70·3)
75·0 
(73·1–76·8)
74·1 
(72·7–75·4)
Stage I 95·6 
(93·4–97·0)
97·8 
(96·6–98·6)
98·2 
(96·4–99·1)
99·3 
(96·0–99·9)
96·3 
(92·4–98·2)
96·9 
(95·6–97·8)
98·4 
(95·9–99·4)
99·3 
(95·7–99·9)
Stage II 90·6 
(88·9–92·0)
91·0 
(90·4–91·5)
94·3 
(93·0–95·4)
94·1 
(92·8–95·1)
91·2 
(88·8–93·1)
86·4 
(85·0–87·6)
94·1 
(91·5–96·0)
92·9 
(90·8–94·6)
Stage III 76·3 
(74·1–78·4)
74·1 
(73·3–74·8)
76·3 
(74·0–78·4)
78·4 
(76·8–79·9)
77·2 
(73·9–80·1)
75·5 
(74·2–76·7)
83·4 
(80·1–86·1)
80·6 
(78·2–82·7)
Stage IV 23·5 
(21·9–25·1)
20·5 
(19·9–21·1)
33·0 
(31·0–35·1)
23·7 
(22·0–25·3)
30·4 
(28·0–32·9)
27·1 
(26·0–28·2)
38·5 
(35·5–41·4)
26·7 
(24·7–28·8)
Unknown stage 47·4 
(44·5–50·2)
47·0 
(45·9–48·0)
45·2 
(42·0–48·4)
69·7 
(66·3–72·9)
67·3 
(63·3–70·9)
57·2 
(55·8–58·6)
56·7 
(52·4–60·8)
73·2 
(69·8–76·3)
Table 2: Age-standardised net survival of patients diagnosed with colorectal adenocarcinoma, 2010–12
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Norway, and Denmark; for rectal cancer, the proportion 
diagnosed with stage I–III rectal cancer was higher in 
England than in Sweden, Denmark, and Norway (table 1).
3-year age-standardised net survival from colon cancer 
was higher in Sweden and Norway than in Denmark and 
England. Rectal cancer survival was consistently higher 
than that for colon tumours in the study countries. 3-year 
survival from rectal cancer was generally similar between 
Denmark, Norway, and Sweden, and lower in England 
(table 2).
Net survival decreased with the increase in disease 
stage (table 2, figure 1). Age-standardised 3-year survival 
for stage I tumours was higher than 95% in all countries 
for both colon and rectal cancers. 3-year survival for 
patients with stage II tumours was about 90% or higher 
in all countries, although survival for patients with rectal 
or colon cancer in England and colon cancer in Denmark 
was notably lower than for patients in Sweden or Norway. 
Although generally higher than 75%, survival for patients 
with stage III colon and rectal cancer was lower in 
England than in Norway and Sweden up to 3 years after 
diagnosis, and in Denmark 1 year after diagnosis. 
Survival from stage IV colon cancer was consistently 
lowest in England and highest in Norway, reaching 
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Figure 1: Age-standardised stage-specific survival for colon (A) and rectal (B) adenocarcinoma diagnosed in 2010–12
Shaded areas represent 95% CI of survival estimates.
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20·5% for England and 33·0% for Norway at 3 years. For 
stage IV rectal cancer, survival was lowest in Sweden and 
England (26·7% in Sweden and 27·1% in England) and 
highest in Norway (38·5%) at 3 years (figure 1).
The overall proportion of patients who received 
resectional surgery was higher for colon than for rectal 
cancer in all countries (table 1). We could not establish 
the surgical status of some patients in Denmark because 
they were not registered in the Danish Colorectal Cancer 
Group database (949 [11·1%] of 8567 patients with colon 
cancer and 263 [6·0%] of 4391 patients with rectal 
cancer). Patients with colorectal cancer who were not 
registered in the Danish Colorectal Cancer Group 
database were more likely to have advanced stage disease 
or missing stage information and be slightly older than 
patients registered in the database. Data on surgery were 
unavailable for 0·3% of patients with colorectal cancer in 
England because their national cancer registry records 
could not be linked to the additional databases (Hospital 
Episode Statistics, National Bowel Cancer Audit, or 
Cancer Waiting Times). We report here analyses of the 
patients with known surgical status. The proportion of 
patients receiving resectional surgery was highest in 
Sweden and lowest in England, for both types of cancer 
(table 1).
The proportion of patients treated with resectional 
surgery was lower in individuals aged 75 years or older 
than in younger patients in each country, and 
international differences in resectional surgery use 
widened with increasing age of patients (table 3). The 
share of patients aged 75 years or older with colon cancer 
with evidence of resectional surgery varied from 
19 078 (59·7%) of 31 946 patients in England to 4429 
(80·9%) of 5474 in Sweden. In patients aged 75 years or 
older with rectal cancer, the share of those with 
resectional surgery varied from 4663 (45·7%) of 10 195 
patients in England to 1342 (61·9%) of 2169 in Sweden. 
Sweden had the highest proportion of patients treated 
with resectional surgery for colon cancer, for each age 
group. For rectal cancer, Norway and Sweden had the 
highest proportions of resectional surgery for all but the 
youngest age group, where Denmark had the highest 
proportion of patients treated. England had the lowest 
proportion of patients treated with resectional surgery 
for rectal cancer in all age groups and for colon cancer in 
the two oldest age groups (table 3).
To account for differences in disease stage distribution, 
we examined the proportion of patients treated by stage 
and age group (figure 2). The proportion of patients with 
colon cancer with evidence of resectional surgery for 
each stage and age group was mostly similar between the 
four countries for stages I and II and in patients aged 
75 years or younger. A higher proportion of patients 
younger than 85 years with stage I colon cancer in 
England had resectional surgery than in other countries. 
However, we observed a steep decline in the proportion 
of patients that had surgical treatment in the older age 
categories in England for each disease stage and for both 
types of cancer, which was not evident in the other 
countries (figure 2). For instance, a higher proportion of 
patients received resectional surgery for stage I colon 
tumours in the 75–84 age group than in the 85 and older 
age group in all countries, but the absolute difference 
between these age groups was 18·0% in England 
Colon tumours Rectal tumours
Denmark England Norway Sweden Denmark England Norway Sweden
Age group, years
18–54 463 (70·2%) 4233 (74·3%) 495 (75·5%) 712 (82·5%) 371 (77·1%) 2065 (66·4%) 248 (71·7%) 465 (74·3%)
55–64 1091 (73·7%) 8951 (75·7%) 990 (73·6%) 1442 (80·3%) 705 (75·4%) 4083 (68·8%) 499 (73·5%) 860 (78·0%)
65–74 2077 (73·1%) 15 541 (76·2%) 1844 (75·5%) 2999 (82·1%) 1072 (71·4%) 5733 (68·6%) 664 (70·2%) 1439 (75·7%)
75–84 1818 (70·8%) 14 834 (67·6%) 1974 (73·9%) 3255 (83·3%) 698 (63·1%) 3962 (54·4%) 510 (63·0%) 1090 (69·0%)
85–99 591 (58·0%) 4244 (42·4%) 720 (58·7%) 1174 (74·9%) 136 (37·2%) 701 (24·1%) 143 (43·2%) 252 (42·8%)
Sex
Men 2917 (70·1%) 25 649 (68·8%) 2925 (71·6%) 4711 (80·2%) 1843 (69·0%) 10 820 (61·1%) 1239 (67·5%) 2427 (70·9%)
Women 3123 (70·9%) 22 154 (68·0%) 3098 (72·9%) 4871 (82·4%) 1139 (66·2%) 5724 (57·8%) 825 (64·7%) 1679 (70·7%)
Disease stage at diagnosis
Stage I 752 (89·6%) 6916 (93·3%) 836 (86·0%) 1328 (90·8%) 741 (93·4%) 5100 (89·9%) 605 (85·8%) 1122 (90·0%)
Stage II 2528 (92·8%) 16 438 (93·8%) 2189 (88·2%) 3541 (97·1%) 928 (89·9%) 3958 (78·9%) 556 (84·4%) 1145 (90·6%)
Stage III 1849 (90·8%) 15 555 (90·1%) 1688 (87·4%) 3282 (95·5%) 900 (84·7%) 5289 (70·3%) 539 (83·6%) 1361 (87·7%)
Stage IV 882 (39·1%) 6263 (39·9%) 1158 (55·6%) 1356 (50·8%) 307 (32·8%) 1293 (25·7%) 331 (47·4%) 376 (29·1%)
Unknown stage 29 (4·1%) 2631 (21·9%) 152 (17·4%) 75 (13·2%) 106 (18·6%) 904 (20·7%) 33 (8·2%) 102 (23·1%)
Total 6040 (70·5%) 47 803 (68·4%) 6023 (72·2%) 9582 (81·3%) 2982 (67·9%) 16 544 (59·9%) 2064 (66·3%) 4106 (70·8%)
Data are n (%). Resectional surgery defined as surgery to remove the primary tumour within 9 months of diagnosis, excluding diagnostic and palliative procedures.
Table 3: Proportion of patients diagnosed with colorectal adenocarcinoma in 2010–12 that received resectional surgery by age, sex, and disease stage
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compared with 2·9–5·5% in the other countries. A 
similar pattern was noted in the other disease stage 
categories. The proportion of patients with colon cancer 
aged 85 years and older with evidence of resectional 
surgery was consistently highest in Sweden for each 
disease stage as compared with the other three countries.
Age at diagnosis (years)Age at diagnosis (years)
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Figure 2: Proportion of patients who underwent resectional surgery for colon (A) and rectal (B) adenocarcinoma by disease stage at diagnosis and age group, 
for diagnoses 2010–12
Error bars are 95% CI. Resectional surgery is defined as surgery to remove the primary tumour within 9 months of diagnosis, excluding diagnostic and palliative 
procedures. Information on surgical status was available for all patients in Norway and Sweden. Information on surgery was missing for some patients in Denmark 
and for a small proportion of patients in England: light grey areas represent the proportion of patients with unknown surgical status by stage and age group; overall 
height of the bars shows the proportion of patients that would receive surgery if all patients with missing treatment data had surgical treatment.
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Among patients younger than 85 years with rectal 
cancer who were diagnosed with stage I or II disease, we 
observed no significant differences in the likelihood of 
being treated with resectional surgery in any of the four 
countries. However, for patients with rectal cancer 
diagnosed with stage III–IV disease, the proportion 
treated was lower in England than in the other countries 
in our study, particularly in the oldest age groups 
(figure 2). We observed an age gradient in the proportion 
of patients receiving resectional surgery with all rectal 
cancer stages in Denmark, England, and Sweden, with 
lower proportions among patients aged 85 years or older 
than among younger patients. The age gradient was 
steeper in England than in other countries. For instance, 
between patients aged 75–84 years and those aged 
85 years or older, the absolute difference in the proportion 
of patients who received resectional surgery for stage III 
rectal tumours was 29·6% in England, 20·9% in Sweden, 
and 12·8% in Denmark. We found no age gradient in the 
proportion of patients treated for rectal cancer in Norway, 
except for patients with stage IV cancer.
To assess the validity of our findings and check whether 
the age differences in the likelihood of patients receiving 
resectional surgery were driven by differences in the 
management of patients diagnosed at aged 90 years or 
older, we repeated the analyses with exclusion of this 
patient group. The patterns we observed persisted in this 
reanalysis (appendix pp 3, 6–7).
Overall, Sweden had the highest survival for colon and 
rectal cancer and the highest proportion of patients 
receiving resectional surgery, compared with those of the 
other countries (although outcomes in Norway were 
generally similar, or better in specific strata, to those in 
Sweden). To highlight any groups of patients who might 
be at a disadvantage in the likelihood of receiving 
resectional surgery compared with patients in other 
countries, we applied the coefficients for Sweden to data 
from the other three countries and interpreted it as the 
probability of a patient receiving resectional surgery if 
they had been treated as in Sweden, given their observed 
age, sex, and disease stage. The number of events per 
parameter was above the recommended threshold of ten 
in all categories,31 at 100 events per parameter for our 
most complex model in the category with fewest events 
(stage IV rectal cancer).
In this hypothetical scenario, changes in the proportion 
of patients with stage I colon or rectal cancer receiving 
resectional surgery would be minor (figure 3). In 
England, Denmark, and Norway there would be a higher 
proportion treated among patients with stage II and III 
colon and rectal cancer, if treated as in Sweden. Overall, 
the largest improvements in the proportion of patients 
receiving resectional surgery would be seen in patients 
with stage II (from 78·9% to 90·7%) or III (from 70·3% 
to 88·2%) rectal cancer in England. The proportion of 
patients receiving resectional surgery for stage IV colon 
cancer in Denmark and England would increase (from 
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Figure 3: Predicted probability of receiving resectional surgery by patient characteristics (age and sex) and 
tumour characteristics (stage at diagnosis)
Error bars are 95% CI. Resectional surgery is defined as surgery to remove the primary tumour within 9 months of 
diagnosis, excluding diagnostic and palliative procedures. *Predicted probabilities of patients receiving 
resectional surgery by applying the coefficients of the Swedish logistic model to the cohorts of patients in each 
country, on the basis of the country-specific distributions of patient characteristics. Light grey areas at the top of 
the bars for Denmark and England represent the proportion of patients with unknown surgical status by stage 
and age group. The overall height of the bars shows the proportion we would observe if all patients with missing 
treatment data had received surgery.
39·1% to 51·1% in Denmark and from 40·0% to 49·8% 
in England)—whereas in Norway, the proportion would 
decrease (from 55·6% to 49·9%) if patients had been 
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treated as in Sweden. The hypothetical decrease in the 
proportion of stage IV patients receiving surgery in 
Norway would be even larger for rectal cancer (from 
47·4% to 28·8%). 
Patients with missing disease stage were slightly older 
than the mean age for each country and cancer type (range 
75·3–77·3 years for colon cancer and 74·5–75·4 years for 
rectal cancer). The proportion of patients with colon cancer 
without known disease stage who had evidence of having 
resectional surgery was lower than that of any known stage 
category in each country and higher in England than in the 
other three countries (table 3). The proportion of patients 
with rectal cancer without known disease stage who had 
evidence of having resectional surgery was higher in 
Sweden than in the other three countries. Survival of 
patients with colorectal cancer without known disease 
stage was higher in Sweden than in Denmark, England, 
and Norway. Additionally, survival of these patients was 
higher than that of patients with known stage III disease 
and lower than that of patients with known stage IV 
disease, in all four countries (table 2).
Discussion
In this study, to understand the mechanisms underlying 
international differences in cancer outcomes, we com-
pared the characteristics of patients diagnosed with 
colorectal adenocarcinoma in Denmark, England, Norway, 
and Sweden. We provide updated figures of up to 3-year 
net survival in these countries, and our results support 
previous findings of lower survival for patients in England 
and, to a lesser degree, in Denmark, than in Sweden or 
Norway.2–5 Our results also support findings that Denmark 
seems to be closing the survival gap with Sweden and 
Norway, particularly for rectal cancer.4,6,24 In the stage-
specific analyses, we noted no significant differences 
between countries in survival for patients diagnosed with 
early stage (I or II) colorectal adenocarcinomas, but wider 
international survival differences in patients with more 
advanced disease stages (III or IV). Additional information 
on treatment, available from specialised colorectal cancer 
registries, helped us to understand these survival 
differences better.
Cancer survival is largely determined by receipt of 
potentially curative treatment, which, in the case of 
colorectal cancer, is primarily surgery. Treatment options 
mainly depend on disease stage and the underlying 
health status of patients, which is determined by their 
comorbidities, frailty, and age.
Clinical guidelines for cancer treatment aim to stan-
dardise and assure adequate cancer care for a population. 
The amount of detail in the national clinical guidelines 
regarding colorectal cancer management varied, with 
recom mendations from England being generally less 
specific than guidelines from Denmark, Norway, and 
Sweden.14,15,32,33 Nonetheless, indications for surgery were 
largely consistent between these countries, especially for 
rectal tumours. Treatment guidelines for colon cancer in 
Denmark, Norway, and Sweden explicitly recommend the 
removal of the part of the bowel that contains the tumour 
and its mesentery (and en-bloc resection, if the visceral 
fascia is compromised because of ingrowth of the tumour 
into neighbouring organs).13,14,32 By contrast, English 
guidelines recognise mesorectal excision as the standard 
surgery for most rectal tumours but do not explicitly 
recommend the corresponding procedure (dissection in 
the embryological plane) for colon tumours.15
None of the guidelines for the countries in our study 
mentions age as an exclusion criterion for receiving 
surgical treatment. However, we found stark differences 
between countries in the proportion of patients aged 
75 years or older who received resectional surgery. Older 
patients (aged 75 years or older with stage II–IV rectal 
cancer or stage IV colon cancer and aged 85 years or 
older for the other stages of rectal and colon cancer) in 
England had a lower probability of receiving resectional 
surgery than patients of a similar age with similar disease 
extension in the other three countries, and a lower 
probability than younger patients in England. Countries 
with better survival—Norway and Sweden—had a higher 
proportion of older patients receiving resectional surgery 
than that in England for most stages of disease. England 
had the steepest negative age gradient in the proportion 
of patients receiving resectional surgery and had a 
survival deficit in comparison with the other three 
countries, particularly for rectal cancer. These patterns 
persisted even after we excluded patients aged 90 years or 
older from the analyses. Conversely, we noted a higher 
proportion of patients younger than 85 years who were 
diagnosed with stage I or II tumours who had evidence 
of resectional surgery in England than in the other three 
countries. Of the countries studied, only England had a 
colorectal cancer screening programme with national 
coverage during the study period.34 The diagnosis and 
treatment of asymptomatic disease through screening 
might explain the high proportion of patients surgically 
treated for early stage disease in the eligible age group in 
England. In the other countries in our study, screening 
was not imple mented at national level during the study 
period34 and could not have affected the disease stage 
distribution or population-based survival.
Although less aggressive treatment for older patients 
might sometimes be justified because of comorbidity or 
frailty, concerns have been raised that some of the 
disparities in age-related cancer care in England arise 
because of clinical decision making on the basis of 
chronological age.35 A 2011 report36 showed lower resection 
rates in older patients with cancer in England during 
2004–06 than those of younger patients, with less than 
2% of patients aged 80 years or older having a major 
resection surgery for six of 13 cancers examined.
Although an increase in the proportion of patients 
receiving resectional surgery does not necessarily trans-
late into better short-term survival because aggressive 
treatment might be associated with high short-term 
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mortality, our findings suggest that international 
differences in survival are, at least in part, determined by 
differences in patient selection practices for surgical 
treatment. Choices in management of older patients 
with colorectal cancer might greatly affect population-
based survival because the mean age at diagnosis is 
about 70 years.37
Patients in countries with a greater proportion of 
patients treated with surgery and better short-term
survival might also have more access to laparoscopic 
surgery or better postoperative care than in the other 
countries. Although there is conflicting evidence about 
the long-term benefit of a laparoscopic versus an open 
surgical approach for rectal cancer,38,39 laparoscopic 
surgery is associated with lower perioperative mortality 
and fewer complications than open surgery.40,41 
In Denmark, the increasing use of laparoscopic surgery 
for colorectal cancer has been associated with a reduction 
in perioperative mortality rates.42 Differences between 
countries in the use of this approach might explain some 
of the differences in the proportion of patients receiving 
surgical treatment and, potentially, in survival. However, 
we were not able to account for this information in our 
analysis because not all datasets had sufficiently complete 
data for this question.
Our study has some limitations. We were able to do 
this international comparison of detailed clinical chara-
cteristics and outcomes for patients with colorectal cancer 
because of the existence of specialised colorectal cancer 
registries. These include core variables that have pre-
viously been examined for comparability and validated—
in these and other European colorectal cancer registries.43 
However, some residual data quality issues might affect 
the comparability of results. Our analyses accounted for 
age, sex, and disease stage, but comparable information 
on comorbidities—an important determi nant of treat-
ment—was not available in all countries. Furthermore, 
comorbidity measures might not reveal a patient’s overall 
health status. Performance status scales, which are 
commonly used to assess patients’ general condition 
(such as their degree of independence) and eligibility for 
specific treatments,44 might not be ideal for older patients 
with cancer, especially those with mul tiple comorbidities.45 
Although comprehensive geriatric assessment scales 
have been proposed and validated,45 they are rarely used, 
documented, or routinely collected.46 Nevertheless, at the 
population level, the burden of cardiovascular disease—
the most common contra indication for surgery—is 
similar in the four countries included in our study.47 
Population-based all-cause mortality and life expectancy 
in older ages are also similar in these four countries 
(appendix p 4), supporting the validity of the findings in 
our study. 
The overall proportion of patients with unknown 
disease stage is notably higher in England than in 
Denmark, Norway, and Sweden. The reasons for stage 
information to be missing are likely to differ according to 
how high or low the proportion of unknown stage is and, 
therefore, probably differ between countries. Patients 
with unknown disease stage had a lower probability of 
receiving resectional surgery than patients with known 
stage, and had similar survival to that of patients with 
advanced disease stages. Therefore, our complete-case 
analysis might overestimate stage-specific survival and 
the proportion of patients receiving resectional surgery 
in England, and provides a conservative estimate of the 
disparities between England and the other three countries 
in our study.
In Denmark, 9·3% of patients were not registered in the 
Danish Colorectal Cancer Group database and thus, their 
treatment status remained undetermined. By contrast 
with the Danish National Cancer Registry, the Danish 
Colorectal Cancer Group database only includes adults 
with a first-time diagnosis of colorectal adenocarcinoma 
treated in Danish public hospitals who were in contact 
with a surgical department.19 Therefore, we calculated a 
potential range of the proportion of patients that might 
have had resectional surgery and estimated upper and 
lower limits of the probable distribution of resectional 
surgery in Denmark. Because of the Danish Colorectal 
Cancer Group database’s exclusion criteria and the stage 
distribution of patients without a Danish Colorectal 
Cancer Group database record, it is probable that a 
substantial number of these patients did not undergo 
resectional surgery. Assuming that none of these patients 
received resectional surgery, the proportion of patients 
with rectal cancer who received resectional surgery was 
still higher in Denmark than in England and similar to 
that in Sweden for most combinations of age and disease 
stage. Nevertheless, these missing data might have 
masked some age and stage trends in the likelihood of 
patients undergoing resectional surgery, especially for 
colon cancer.
We were not able to ascertain treatment intent, residual 
disease status, venous invasion status, or postoperative 
complications in patients who received resectional 
surgery. We expect that the prognosis of patients who 
underwent resectional surgery but had residual disease or 
any postoperative complication was poorer than those 
without residual disease. Systematic differences in the 
distribution of such patients between these four countries, 
or differences in their perioperative management, might 
affect the between-country comparability of these results. 
Further more, patients with non-resectable tumours in 
better-performing countries might be more likely to be 
offered other treatment (such as treatment to prolong life 
or make tumours amenable to resection) than patients 
in worse-performing countries. For example, clinical 
guidelines in Norway and Sweden describe the 
importance of neo-adjuvant or conversion treatment of 
metastatic tumours to render them resectable,13,14 whereas 
guidelines in England prioritise symptom control and 
state that initial systemic treatment followed by surgery 
should be considered only if both primary and metastatic 
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tumours are judged to be resectable.15 Moreover, in 
countries that frequently use neo-adjuvant therapy with 
delayed surgery for rectal cancer, the resulting down-
staging could cause an under estimation of the differences 
in stage-specific survival when these countries are 
compared with settings where neo-adjuvant treatment is 
more variable or followed by immediate surgery.
The completeness and granularity of the data collected 
by the colorectal cancer registries regarding chemo-
therapy and radiotherapy varied greatly during the study 
period—from complete registration of radiotherapy 
protocols in Norway and Sweden to a high proportion of 
missing information in England. These inconsistencies 
meant that including radiotherapy and chemotherapy in 
our analyses was not possible (appendix p 5). Adjuvant 
chemotherapy is associated with improved outcomes in 
stage III colon cancer and is used universally, but for 
stage II colon cancer and rectal cancer (in general) its 
value and therefore its use have been more variable.48–50 
Neo-adjuvant radiotherapy decreases recur rence rates, 
but evidence for its effect on survival is conflicting and 
so use also varies within countries16,51 and between 
countries.17 The use of targeted therapy in com bination 
with chemotherapy might help to make tumours 
amenable to resection in some patients with metastatic or 
locally advanced disease,52 but no survival benefit has 
been shown for this combination.53 For patients with 
metastatic disease treated with non-curative intent, 
optimal use of systemic therapy contributes to longer 
survival.52,54 Variability between countries in the use of 
these additional therapies, and other differences in 
oncological care beyond surgery, might also contribute to 
the observed differences in survival.
Despite the limitations of the data included in our study, 
we have identified important international differences in 
the distribution of resectional surgery by age and disease 
stage. The main data quality issue (the higher proportion 
of patients with unknown disease stage in England) is 
likely to have led to a conservative estimate of the 
differences found in stage-specific survival outcomes in 
England compared with those of other countries. We 
noted that differences in survival between patients with 
colorectal cancer treated in England, Denmark, Norway, 
and Sweden tended to increase with time after diagnosis, 
and it is possible that these differences between countries 
would widen with longer follow-up.
Changes in practice during and after the study period 
are likely to affect future trends. Over the past two or three 
decades, colorectal cancer outcomes have improved in all 
the countries compared in our study.3,24,55 The centralisation 
and specialisation of colorectal cancer surgery have been 
suggested as important drivers of this improvement.4 A 
2012 Cochrane review56 found a clear association between 
operative mortality and 5-year survival with hospital and 
surgeon caseload and specialisation. Specialisation of 
surgeons has led to more widespread and aggressive 
treatment of metastatic disease, with increased use of 
chemotherapy and resection of metastases. However, it is 
likely that centralisation and specialisation vary between 
the four countries in our study, and these changes in 
practice are also likely to affect patient survival differently 
in these countries.4,6
Expedited referral routes were initiated in England and 
Denmark in the 2000s, in response to low cancer survival 
related to system delays.57,58 Similar rapid referral routes 
were introduced in Norway and Sweden in 2016, following 
the Danish experience. Although diagnostic delays are 
important factors in cancer care, the effect of these 
referral routes on cancer survival remains uncertain.
In Denmark, a nationwide screening programme with 
a monitoring database was introduced in 2014.59 The 
Norwegian Directorate of Health is planning to introduce 
a national colorectal cancer screening programme in 
Norway in 2019, offering a faecal immunochemical test 
or colonoscopy to individuals when they turn 55 years.60 
Similarly, a national colorectal cancer screening pro-
gramme is due to be implemented in Sweden in 2019, 
following regional screening programmes.61 In England, 
a one-off screening test with flexible sigmoidoscopy for 
people aged 55 years is being rolled out.62 With increases 
in diagnosis and treatment of asymptomatic disease, it is 
likely that survival and the proportion of patients treated 
for early stage disease will increase in the future.
Since 2013, surgeon-specific outcomes have been 
reported annually as quality measures in England.63 It is 
hoped that this increase in accountability will lead to 
improvements in patient care. However, these changes 
might also affect patient selection for surgery. The major 
reorganisation of the NHS in 2013,64 alongside sub stantial 
resource constraints in the NHS65 in the past decade, has 
had a potentially negative effect on cancer services. For 
instance, the 62-day treat ment waiting time target—the 
aim that a patient should wait no more than 2 months 
from the date that the hospital receives an urgent referral 
for suspected cancer to the start of their treatment—has 
been missed for several quarters running, showing that 
services are unable to meet the demands placed on them.66 
Given the ongoing financial pressures and austerity in the 
UK and the NHS, the future trends in survival for patients 
with cancer in England are uncertain.
Our findings have important policy implications, 
suggesting that the colorectal cancer survival deficit in 
England as compared with Denmark, Norway, and 
Sweden can be attributed partly to shortfalls in provision 
of surgical treatment. We showed that older patients in 
England, in particular, were less likely to receive re-
sectional surgery than patients with similar characteristics 
in the other countries in our study. We posit that increases 
in the proportion of patients receiving resectional surgery 
might translate into better longer-term outcomes in 
England, provided that adequate postoperative care is 
also available.
Improving the capture of information on patients 
with colorectal cancer in specialised clinical registries, 
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including data from individuals who are not eligible for 
surgery, would allow a more complete population-based 
comparison of colorectal cancer outcomes. Complete and 
comparable data on comorbidities, frailty, and additional 
therapies are required to improve understanding of 
international differences and inequalities in cancer 
outcomes.
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